Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Virios Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
VIRI
Nasdaq
8731
https://www.virios.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Virios Therapeutics Inc
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
- Mar 26th, 2024 1:15 pm
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
- Feb 29th, 2024 2:15 pm
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
- Feb 28th, 2024 2:15 pm
VIRI: Moving IMC-2 into Phase 2 Program in Long COVID
- Feb 7th, 2024 11:00 am
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
- Jan 22nd, 2024 2:00 pm
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
- Jan 2nd, 2024 12:05 pm
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcript
- Nov 14th, 2023 2:55 pm
VIRI: Provides Overview of Phase 3 Program in Fibromyalgia
- Nov 13th, 2023 1:00 pm
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 13th, 2023 12:05 pm
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
- Nov 6th, 2023 12:05 pm
Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023
- Oct 12th, 2023 11:05 am
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement
- Sep 18th, 2023 11:05 am
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023
- Sep 12th, 2023 11:05 am
VIRI: Phase 3 Program in Fibromyalgia to Initiate in mid-2024…
- Aug 15th, 2023 11:48 am
Virios Therapeutics Announces Halt to At-The-Market Offering Sales
- Aug 14th, 2023 11:05 am
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q2 2023 Earnings Call Transcript
- Aug 12th, 2023 1:40 pm
Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
- Aug 10th, 2023 11:05 am
Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia
- Aug 9th, 2023 11:05 am
Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
- Aug 3rd, 2023 8:05 pm
VIRI: Encouraging Results for IMC-2 in Long COVID…
- Jul 24th, 2023 12:40 pm
Scroll